4 Ways Amgen Works to Cut Heart Attacks and Strokes Through LDL-C Testing

In the battle against cardiovascular disease (CVD) — one of the most underappreciated public health crises of our time — testing for LDL (bad) cholesterol is vital. LDL-C is a crucial modifiable risk factor for CVD, but it's not just about numbers and medical jargon — it's about intervening early, creating a personalized treatment plan, and taking action.

Click above to watch this short curtain raiser message from Jyothis George, Medical VP, Global & US Therapeutic Area Head, Cardiometabolic.

At this year's European Society of Cardiology (ESC) congress, Amgen's CVD experts will be highlighting four important steps the company is taking to help turn the tide on one of the world's greatest public health challenges.

1. LDL-C Action Summit

Earlier this year, Amgen hosted the first-ever annual LDL-C Action Summit by convening representatives from the American College of Cardiology (ACC), American Heart Association (AHA), Cardio Health Alliance, Family Heart Foundation, the National Lipid Association (NLA), National Forum for Heart Disease & Stroke Prevention and Baim Institute to discuss strategies and opportunities for improving lipid management among the highest risk patients. Now at ESC, we are hosting our next summit in this ongoing effort to work collaboratively and tackle unmanaged LDL cholesterol.

2. #Aimlow

The  #AimLow campaign was created to help reach Amgen's goal of cutting the number of cardiovascular events in half by 2030. #AimLow calls on healthcare professionals to help their patients with cardiovascular disease aim for and maintain low LDL-C levels consistent with treatment guidelines by getting tested, getting educated and taking action.

3. Free LDL-C Testing during National Cholesterol Education Month

September is National Cholesterol Education Month and to help raise awareness, Amgen is sharing information about how to obtain free LDL-C tests to anyone who signs up at – terms and conditions apply. It's important that patients know their LDL-C level as it helps them better understand their risk and take action when it comes to their health.

4. LDL Awareness to Action Implementation Consortium (LATAIC) Meeting

LATAIC is a network of champions driving action to scale implementation efforts to improve LDL-C testing and evidence-based treatment. At ESC, on Saturday, August 26 at 7:30am CEST, LATAIC will be meeting to discuss several ongoing initiatives, as well as review additional innovative proposals from five organizations.

For updates, live content, and to stay informed throughout ESC, follow our Amgen social media accounts on Twitter, LinkedIn, Instagram, TikTok, YouTube and Threads.

Share This Story